Genotropin GoQuick

Genotropin GoQuick





Zuellig Pharma
Concise Prescribing Info
Recombinant somatropin
Replacement therapy in adults w/ pronounced growth hormone deficiency (GHD). Growth disturbance due to insufficient secretion of growth hormone or associated w/ Turner syndrome or chronic renal insufficiency in childn. Growth disturbance in short childn born small for gestational age (SGA) w/ birth wt &/or length <2 SD, who failed to show catch-up growth by ≥4 yr. Prader-Willi syndrome for improvement of growth & body composition.
Dosage/Direction for Use
SC GHD Adult Restart w/ 0.2-0.5 mg daily. Childn 0.025-0.035 mg/kg daily or 0.7-1 mg/m2 daily. Short childn born SGA 0.035 mg/kg daily or 1 mg/m2 daily until final height is reached. Chronic renal insufficiency 0.045-0.05 mg/kg daily or 1.4 mg/m2 daily. Onset GHD Adult Start w/ 0.15-0.3 mg daily. Patient who continue growth hormone therapy after childhood GHD Restart w/ 0.2-0.5 mg daily, adjust dose gradually according to requirements. Patient >60 yr 0.1-0.2 mg daily. Prader-Willi syndrome Childn 0.035 mg/kg daily or 1 mg/m2 daily. Max daily dose: 2.7 mg. Turner syndrome 0.045-0.05 mg/kg daily or 1.4 mg/m2 daily.
Hypersensitivity. Evidence of tumour activity. Patients w/ acute critical illness suffering complications following open heart surgery, abdominal surgery, multiple accidental trauma, acute resp failure. Childn w/ closed epiphyses.
Special Precautions
Discontinue use if papilloedema is confirmed. Not recommended to initiate treatment near onset of puberty in short childn born SGA. Leukemia; myositis; pancreatitis; acute critical illness; upper airway obstruction, sleep apnoea, resp infections. May reduce insulin sensitivity. Closely monitor patients w/ diabetes, glucose intolerance or additional risk factors for diabetes during therapy. Monitor thyroid function; signs of scoliosis. May unmask previously undiagnosed central hypoadrenalism. Relapse of GHD secondary to malignant disease treatment. Formation of Ab. Strict calorie-restricted diet & wt control in patients w/ Prader-Willi syndrome. Measure fasting insulin & blood glucose prior to & annually in SGA childn. Assess renal function prior to initiation of therapy. Discontinue treatment at renal transplantation. Not recommended during pregnancy & in women of childbearing potential not using contraception. Lactation. Elderly >80 yr. Examine childn limping during treatment.
Adverse Reactions
Inj site reaction, arthralgia, peripheral oedema. Paresthesia, benign intracranial HTN, carpal tunnel syndrome, myalgia, musculoskeletal stiffness.
Drug Interactions
Inhibited growth-promoting effects w/ glucocorticoids. Increased clearance of CYP450 3A4-metabolized compd eg, sex steroids, corticosteroids, anticonvulsants & ciclosporin.
ATC Classification
H01AC01 - somatropin ; Belongs to the class of somatropin and somatropin agonists. Used in anterior pituitary lobe hormone and analogue preparations.
Genotropin GoQuick inj 12 mg
Genotropin GoQuick inj 5.3 mg
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in